<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499573</url>
  </required_header>
  <id_info>
    <org_study_id>NCPHOI-2020-07</org_study_id>
    <nct_id>NCT04499573</nct_id>
  </id_info>
  <brief_title>Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL</brief_title>
  <official_title>Safety and Efficiency of Anti-CD19/CD22 Tandem Fully Human Chimeric Antigen Receptor (CAR)-Transduced T-cell Therapy for Pediatric and Young Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: a Single Centre, Non-randomised, Open Label Phase I-II Clinical Trial of Automatically Produced Cell Therapy Product MB-CAR-T19-22 Using CliniMACS Prodigy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficiency of autologous CD19/CD22&#xD;
      CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory&#xD;
      B-lineage acute lymphoblastic leukemia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objectives of the study are:&#xD;
&#xD;
        -  To investigate the incidence of adverse events of grade 3-5 within after CD19/CD22 CAR&#xD;
           lymphocyte infusion by day 28,&#xD;
&#xD;
        -  To evaluate the incidence of complete remission and MRD-negative CR by day 28&#xD;
&#xD;
        -  To evaluate the long-term effectiveness of CD19/CD22 CAR-T therapy (cumulative incidence&#xD;
           of relapse, event-free survival, overall survival) at 1, 2, and 5 years after infusion.&#xD;
&#xD;
        -  To evaluate the persistence of CD19/CD22 CAR-T cells and duration of B-cell aplasia (&lt;1%&#xD;
           B-cells in the blood) and hypogammaglobulinemia In order to prevent the development of&#xD;
           CRS, all patients will receive an infusion of tocilizumab at 8 mg/kg body weight on day&#xD;
           0 before CAR-T cells infusion.&#xD;
&#xD;
      Step-down and step-up dosing will be used to adapt the trial to the scenario of excess&#xD;
      toxicity and/or suboptimal effect. Reevaluation of dosing will be done for each cohort&#xD;
      separately after the enrollment 5th study subject reaches day 28 or earlier if the threshold&#xD;
      for excess toxicity or suboptimal effect is achieved.&#xD;
&#xD;
      Based on interim analysis in March 2021 after the enrollment 5th study subject reaches day 28&#xD;
      study population will be divided into three cohorts:&#xD;
&#xD;
        1. CD19-positive (both CD19 and CD22 expressed on over 50% of leukemia cells), low and high&#xD;
           disease burden.&#xD;
&#xD;
        2. CD19-negative (CD22 expressed on over 50% of leukemia cells) low and high disease&#xD;
           burden;&#xD;
&#xD;
        3. Allogeneic HSCT+ allogeneic CAR-T cohort&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of grade 3-5 SAE</measure>
    <time_frame>1 month</time_frame>
    <description>Safety:&#xD;
Toxicity evaluation following CD19/CD22 CAR T-cell infusion:&#xD;
- incidence of grade 3-5 SAE (according CTCAE v.5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of grade 3-5 Severe Cytokine Release Syndrome</measure>
    <time_frame>1 month</time_frame>
    <description>Safety:&#xD;
Toxicity evaluation following CD19/CD22 CAR T-cell infusion:&#xD;
- incidence of grade 3-5 Severe Cytokine Release Syndrome (according ASTCT consensus)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of grade 3-5 ICANS</measure>
    <time_frame>1 month</time_frame>
    <description>Safety:&#xD;
Toxicity evaluation following CD19/CD22 CAR T-cell infusion:&#xD;
- incidence of grade 3-5 ICANS (according to ASTCT consensus)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of complete remission</measure>
    <time_frame>1 month</time_frame>
    <description>Efficacy:&#xD;
- Rate of complete remission among all enrolled patients (Intent-to-Treat population)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of MRD-negative remission</measure>
    <time_frame>1 month</time_frame>
    <description>Efficacy:&#xD;
- Rate of MRD-negative remission among all patients (Intent-to-treat population)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>March 2021 amendment: incidence of graft failure before day 100 (only for HSCT cohort)</measure>
    <time_frame>100 days</time_frame>
    <description>Safety:</description>
  </primary_outcome>
  <primary_outcome>
    <measure>March 2021 amendment: incidence of aGVHD grade 2-4 (only for HSCT cohort)</measure>
    <time_frame>100 days</time_frame>
    <description>Safety:</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of MRD-negative remission</measure>
    <time_frame>2 years</time_frame>
    <description>Efficacy:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence/frequency of CD19/CD22 lymphocytes in peripheral blood (flow cytometry)</measure>
    <time_frame>2 years</time_frame>
    <description>Efficacy:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of B-cell aplasia and hypogammaglobulinemia</measure>
    <time_frame>2 years</time_frame>
    <description>Efficacy:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Efficacy:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and adverse effects long-term</measure>
    <time_frame>5 years</time_frame>
    <description>Safety:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>March 2021 amendment: Incidence of chronic GVHD (only for HSCT cohort)</measure>
    <time_frame>5 years</time_frame>
    <description>Safety:</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>B-ALL</condition>
  <arm_group>
    <arm_group_label>intervention/treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:&#xD;
Patient (cohort 1 and 2) or donor (cohort 3) leukapheresis&#xD;
Drug therapy:&#xD;
Fludarabine 120 mg/m2&#xD;
Cyclophosphamide 750 mg/m2&#xD;
Etoposide 450 mg/m2&#xD;
Cytarabine 900 mg/m2&#xD;
Dexamethasone 30 mg/m2&#xD;
Tocilizumab 8 mg/kg BW&#xD;
Biological:&#xD;
Cohort 1 and 2: autologous CD19/CD22 CAR-T lymphocytes, dose 0.15 - 1.5х106/kg&#xD;
Cohort 3: allogeneic CD19/CD22 CAR-T lymphocytes, dose 0.1х106/kg + allogeneic HSCT from a haploidentical or matched related donor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD19/CD22 CAR-T</intervention_name>
    <description>The treatment plan will be based on stratification by the initial leukemia burden.&#xD;
Patients with &quot;low disease burden&quot; will receive a lymphodepletion chemotherapy of fludarabine (total dose 120mg/m2) and cyclophosphamide (total dose 750mg/m2) over 5 days.&#xD;
Patients will &quot;high disease burden&quot; will receive a lymphodepletion chemotherapy of fludarabine (total dose 120 mg/m2), cyclophosphamide (total dose 750 mg/m2), cytarabine (total dose 900 mg/m2), etoposide (total dose 450 mg/m2), dexamethasone (total dose 30 mg/m2) over 5 days.&#xD;
Based on interim analysis the following dosing approach will be implemented starting April 2021:&#xD;
Cohort 1: CD19+ disease, low and high burden: 1st dose - 150k/kg, 2nd dose - 850k/kg Cohort 2: CD19- disease, low and high burden: 1st dose - 500k/kg, 2nd dose - 500k/kg Cohort 3: HSCT+CAR-T: 100k/kg</description>
    <arm_group_label>intervention/treatment</arm_group_label>
    <other_name>Fludarabine</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Cytarabine</other_name>
    <other_name>Etoposide</other_name>
    <other_name>Dexamethasone</other_name>
    <other_name>Tocilizumab</other_name>
    <other_name>Allogeneic HSCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to give informed consent (for patients &gt; 14 years old). For subjects &lt; 18&#xD;
             years old their legal guardian must give informed consent&#xD;
&#xD;
          -  CD19 or CD22 expression must be detected on greater than 50% of leukemic cells by flow&#xD;
             cytometry&#xD;
&#xD;
          -  Presence of a measurable mass of tumor cells in the bone marrow or extramedullary&#xD;
             sites at the time of patient's inclusion in the study&#xD;
&#xD;
          -  Patients with relapsed or refractory CD19 and CD22-expressing B-cell ALL:&#xD;
&#xD;
               -  Induction failure&#xD;
&#xD;
               -  MRD ≥ 0,1% after 2nd chemotherapy course for high-risk group patients.&#xD;
&#xD;
               -  First bone marrow or combined relapse of acute lymphoblastic leukemia, no CR or&#xD;
                  MRD ≥ 0,1% after 1-course 2nd line therapy&#xD;
&#xD;
               -  Second and further relapse of ALL&#xD;
&#xD;
               -  Relapse or MRD ≥ 0,1% of ALL after hematopoietic stem cell transplant (&gt; 60 days&#xD;
                  post alloHSCT)o There must be no available alternative approved curative&#xD;
                  therapies&#xD;
&#xD;
          -  Patient Clinical Performance Status: Karnofsky &gt;50% or Lansky &gt;50%&#xD;
&#xD;
          -  Patient Life Expectancy &gt; 4 weeks&#xD;
&#xD;
          -  Patients recovered from acute toxic effects of prior chemotherapy, immune- or&#xD;
             radiotherapy&#xD;
&#xD;
          -  Patient absolute blood naïve (CD45RA+) T-lymphocyte count ≥ 50/mm3&#xD;
&#xD;
          -  Patient cardiac function left ventricular ejection fraction greater than or equal to&#xD;
             40% by MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by&#xD;
             ECHO or left ventricular ejection fraction greater than or equal to 50% by ECHO.&#xD;
&#xD;
          -  Patients who agree to long-term follow up for up to 5 years (if received CD19/CD22&#xD;
             CAR-T cell infusion)&#xD;
&#xD;
          -  March 2021 amendment: Healthy HLA-matched related or haploidentical donor (only for&#xD;
             HSCT cohort)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;50% expression of both CD19 and CD22 on the leukemic population&#xD;
&#xD;
          -  Active (detectable viremia) hepatitis B, C or HIV infection&#xD;
&#xD;
          -  Oxygen saturation ≤ 90%&#xD;
&#xD;
          -  Bilirubin &gt;3x upper norma limit&#xD;
&#xD;
          -  Creatinine &gt;3x upper norma limit&#xD;
&#xD;
          -  Active acute GVHD overall grade ≥2 (Seattle criteria)&#xD;
&#xD;
          -  Moderate/severe chronic GVHD (NIH consensus) requiring systemic steroids&#xD;
&#xD;
          -  Clinical signs of grade &gt; 3 CNS disorders (seizure disorder, paresis, aphasia,&#xD;
             cerebrovascular, ischemia/hemorrhage, severe brain injuries, dementia, cerebellar&#xD;
             disease, organic brain syndrome, psychosis, coordination or movement disorder)&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Active (unresolved) severe infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Maschan</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Center for Pediatric Hematology , Moscow, Russian Federation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olga Molostova</last_name>
    <phone>+7(495)2876570</phone>
    <phone_ext>7535</phone_ext>
    <email>Olga.molostova@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Molostova</last_name>
      <phone>84956647078</phone>
      <phone_ext>7535</phone_ext>
      <email>Olga.molostova@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>July 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-ALL</keyword>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>CAR-T</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

